• Explore /
  • Poster
  • / Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.

Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.

Abstract Poster

Authors

null

Mark H. O'Hara

Abramson Cancer Center, Philadelphia, PA

Mark H. O'Hara , Thomas Benjamin Karasic , Irina Vasilevskaya , Maryann Redlinger , Arturo Loaiza-Bonilla , Ursina R. Teitelbaum , Bruce J. Giantonio , Nevena Damjanov , Kim Anna Reiss , Mark Alan Rosen , Daniel F Heitjan , Andrea B. Troxel , Ravi K. Amaravadi , Peter J. O'Dwyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01206530

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3545)

DOI

10.1200/JCO.2017.35.15_suppl.3545

Abstract #

3545

Poster Bd #

168

Abstract Disclosures

Similar Posters

First Author: Sunil Sharma

First Author: Arturo Loaiza-Bonilla

Poster

2024 ASCO Gastrointestinal Cancers Symposium

<span>Tumor genomics and sidedness to predict outcomes in metastatic colorectal cancer (mCRC).</span>

Tumor genomics and sidedness to predict outcomes in metastatic colorectal cancer (mCRC).

First Author: Patrick M Boland

First Author: Gemma Bruera